Intron A (interferon alfa-2b) — CareFirst (Caremark)

Initial criteria

• Authorization may be granted for treatment of hairy cell leukemia.

Reauthorization criteria

• Authorization of up to a total of 6 months may be granted for continued treatment when the member is receiving clinical benefit and there is no evidence of unacceptable toxicity while on current regimen.

Approval duration

6 months